Does nonmetastatic castration-resistant prostate cancer still exist?

被引：0
|
作者：
Celestia S. Higano
机构：
[1] University of Washington,Division of Medical Oncology, Department of Medicine
[2] Fred Hutchinson Cancer Research Center,undefined
[3] Seattle Cancer Care Alliance,undefined
来源：
Nature Reviews Clinical Oncology | 2018年 / 15卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
After almost 20 years of negative trials of novel therapies for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), two androgen receptor antagonists have shown favourable outcomes in phase III trials involving patients with high-risk nmCRPC. Herein, the history of nmCRPC and clinical trials in this disease setting are discussed and a perspective on molecular imaging and clinical management of nmCRPC is offered.
引用
收藏
页码：350 / 351
页数：1
相关论文
共 50 条
  • [31] Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity
    Lopez-Campos, Fernando
    Conde-Moreno, Antonio
    Barrado Los Arcos, Marta
    Gomez-Caamano, Antonio
    Garcia-Gomez, Raquel
    Hervas Moron, Asuncion
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (11):
  • [32] Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
    George, Daniel J.
    Morgans, Alicia K.
    Constantinovici, Niculae
    Khan, Nasreen
    Khan, Javeed
    Chen, Guifang
    Hlebec, Vlasta
    Shore, Neal D.
    JAMA NETWORK OPEN, 2024, 7 (08)
  • [33] ARAMIS: Efficacy and Safety of Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 2 - 5
  • [34] PSMA PET-CT redefines nonmetastatic castration-resistant prostate cancer
    Ost, Piet
    NATURE REVIEWS UROLOGY, 2020, 17 (03) : 133 - 134
  • [35] Impact of Darolutamide on Local Symptoms in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 11 - 12
  • [36] ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC).
    Fizazi, Karim
    Shore, Neal D.
    Tammela, Teuvo
    Ulys, Albertas
    Vjaters, Egils
    Polyakov, Sergey
    Jievaltas, Mindaugas
    Luz, Murilo
    Alekseev, Boris Y.
    Kuss, Iris
    Kappeler, Christian
    Snapir, Amir
    Sarapohja, Toni
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [37] Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction
    John Esther
    Benjamin L. Maughan
    Neysi Anderson
    Neeraj Agarwal
    Andrew W. Hahn
    Current Treatment Options in Oncology, 2019, 20
  • [38] Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer
    Appukkuttan, Sreevalsa
    Farej, Ryan
    Miles, LaStella
    Purser, Molly
    Wen, Lonnie
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (02): : 166 - 174
  • [39] Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer
    Rasmussen, Kelli M.
    Patil, Vikas
    Li, Chunyang
    Yong, Christina
    Appukkutan, Sreevalsa
    Grossman, Jamie Partridge
    Jhaveri, Jay
    Halwani, Ahmad S.
    JAMA NETWORK OPEN, 2023, 6 (10) : E2337272
  • [40] Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease
    Henriquez, Ivan
    Spratt, Daniel
    Gomez-Iturriaga, Alfonso
    Abuchaibe, Oscar
    Counago, Felipe
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2021, 12 (01): : 6 - 12
12345